@phdthesis{Nordbeck2022,
  author    = {Nordbeck, Arno Wilhelm},
  title     = {Roux-en-Y Magenbypass spezifische metabolomische Ver{\"a}nderungen in Urin, Faeces und Plasma - Charakterisierung im Zucker (fa/fa) Rattenmodel},
  doi       = {10.25972/OPUS-26869},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-268694},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Es wurde ein etabliertes Tiermodell mit Zucker Ratten (fa/fa) verwendet, um postoperative, gewichtsverlustunabh{\"a}ngige metabolomische Effekte des Roux-en-Y Magenbypass (RYGB) zu ermitteln. Es galt Hypothesen zu generieren, welche globalen Metabolite die positiven Auswirkungen des Magenbypass verursachen k{\"o}nnen. Beispielsweise war γ-Amino-Butters{\"a}ure (GABA) f{\"a}kal nach RYGB vermehrt nachweisbar und somit ein potentieller Mediator f{\"u}r einen Bypass-spezifischen Effekt. Die Ergebnisse zeigen die Komplexit{\"a}t der metabolomischen Ver{\"a}nderungen durch RYGB und Nahrungsrestriktion. Die genauen Mechanismen nach metabolisch-bariatrischer Operation, die zu dem therapeutischen Effekt f{\"u}hren, bleiben weiterhin unklar, sodass es weiterer Studien bedarf, um kausale Zusammenh{\"a}nge nachzuweisen.},
  subject      = {Tiermodell},
  language  = {de}
}
@article{MetznerHerzogHeckeletal.2022,
  author    = {Metzner, Valentin and Herzog, Gloria and Heckel, Tobias and Bischler, Thorsten and Hasinger, Julia and Otto, Christoph and Fassnacht, Martin and Geier, Andreas and Seyfried, Florian and Dischinger, Ulrich},
  title     = {Liraglutide + PYY\(_{3-36}\) combination therapy mimics effects of Roux-en-Y bypass on early NAFLD whilst lacking-behind in metabolic improvements},
  series = {Journal of Clinical Medicine},
  volume    = {11},
  journal   = {Journal of Clinical Medicine},
  number    = {3},
  issn      = {2077-0383},
  doi       = {10.3390/jcm11030753},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-255244},
  year      = {2022},
  abstract  = {Background: Treatment options for NAFLD are still limited. Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), has been shown to improve metabolic and histologic markers of NAFLD. Glucagon-like-peptide-1 (GLP-1) analogues lead to improvements in phase 2 clinical trials. We directly compared the effects of RYGB with a treatment using liraglutide and/or peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) in a rat model for early NAFLD. Methods: Obese male Wistar rats (high-fat diet (HFD)-induced) were randomized into the following treatment groups: RYGB, sham-operation (sham), liraglutide (0.4 mg/kg/day), PYY\(_{3-36}\) (0.1 mg/kg/day), liraglutide+PYY\(_{3-36}\), and saline. After an observation period of 4 weeks, liver samples were histologically evaluated, ELISAs and RNA sequencing + RT-qPCRs were performed. Results: RYGB and liraglutide+PYY\(_{3-36}\) induced a similar body weight loss and, compared to sham/saline, marked histological improvements with significantly less steatosis. However, only RYGB induced significant metabolic improvements (e.g., adiponectin/leptin ratio 18.8 ± 11.8 vs. 2.4 ± 1.2 in liraglutide+PYY\(_{3-36}\)- or 1.4 ± 0.9 in sham-treated rats). Furthermore, RNA sequencing revealed a high number of differentially regulated genes in RYGB treated animals only. Conclusions: The combination therapy of liraglutide+PYY\(_{3-36}\) partly mimics the positive effects of RYGB on weight reduction and on hepatic steatosis, while its effects on metabolic function lack behind RYGB.},
  language  = {en}
}